Bone Scan Index

Quantification of bone scan
in advanced prostate cancer

As an imaging biomarker, Bone Scan Index (BSI), can support physicians to determine treatment response, and to prognosticate development in patients with advanced prostate cancer and bone metastases. For this patient group, the BSI can add value to Prostate Specific Antigen (PSA). Until the EXINI product was launched, there was no automated process providing accurate BSI calculations. Thanks to EXINI, BSI is developing into a widespread tool for nuclear medicine physicians, urologists and oncologists.

BSI assessment can also play an important role in clinical trials of new drugs aimed at this patient group.

With the help of EXINI BSI product, BSI can be brought into daily clinical work were it will assist physicians in their effort to efficiently treat prostate cancer.